ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2015
Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Acupuncture treatment vs. cognitive rehabilitation for post-stroke cognitive impairment: A systematic review and meta-analysis of randomized controlled trials.Frontiers in neurology · 2023Pooled it
- Pooled it
- Feasibility and Preliminary Efficacy of a Multimodal Approach to Increase Physical Activity in Older Adults With Memory Complaints: The Education for Action Study.Journal of aging and physical activity · 2022Trial
- Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Dementia Severity Associated With Unmet Caregiving Needs During Skilled Home Health Care.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2026Article
- Healthcare Spending Before and After Mild Cognitive Impairment Diagnosis: Evidence from the NHIS-NHID in Korea.Healthcare (Basel, Switzerland) · 2025Article
- Cognitive Impairment and Physical Dysfunction Associated With Unplanned Dialysis Initiation.Kidney international reports · 2025Article
- The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors.Alzheimer's research & therapy · 2025Article
- Associations Between Trail-Making Test Black and White Performance and Gray Matter Volume in Community-Dwelling Cognitively Healthy Adults Aged 40 to 80 Years.Journal of clinical medicine · 2025Article
- Animal-derived foods, physical activities, and mild cognitive impairment among Chinese older adults: findings from CLHLS (2008-2018).BMC public health · 2025Article
- Incremental Healthcare Costs of Dementia and Cognitive Impairment in Community-Dwelling Older Adults: A Prospective Cohort Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.Neurology and therapy · 2024Article
- Examining the Role of Neuroticism Polygenic Risk in Late Life Cognitive Change: A UK Biobank Study.Behavioral sciences (Basel, Switzerland) · 2024Article
- Patterns in health care use and intensity for diagnosed and undiagnosed cognitive impairment in the older australian community: Implications for primary care management.SSM - population health · 2024Article
- 2024 Alzheimer's disease facts and figures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.Journal of Alzheimer's disease : JAD · 2024Article
- Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States.The journal of prevention of Alzheimer's disease · 2024Article
- Clinical parameters affect the structure and function of superficial pyramidal neurons in the adult human neocortex.Brain communications · 2024Article
- Disease Burden and Progression in Patients with New-Onset Mild Cognitive Impairment and Alzheimer's Disease Identified from Japanese Claims Data: Evidence from the LIFE Study.Journal of Alzheimer's disease : JAD · 2023Article
- Sympathetic Vagal Balance and Cognitive Performance in Young Adults during the NIH Cognitive Test.Journal of functional morphology and kinesiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundObjective cost estimates and source of cost differences are needed across the spectrum of cognition, including cognitively normal (CN), mild cognitive impairment (MCI), newly discovered dementia, and prevalent dementia.
methodsSubjects were a subset of the Mayo Clinic Study of Aging stratified-random sampling of Olmsted County, MN, residents aged 70 to 89 years. A neurologist reviewed provider-linked medical records to identify prevalent dementia (review date = index). Remaining subjects were invited to participate in prospective clinical/neuropsychological assessments; participants were categorized as CN, MCI, or newly discovered dementia (assessment date = index). Costs for medical services/procedures 1-year pre-index (excluding indirect and long-term care costs) were estimated using line-item provider-linked administrative data. We estimated contributions of care-delivery site and comorbid conditions (including and excluding neuropsychiatric diagnoses) to between-category cost differences.
resultsAnnual mean medical costs for CN, MCI, newly discovered dementia, and prevalent dementia were $6042, $6784, $9431, $11,678, respectively. Hospital inpatient costs contributed 70% of total costs for prevalent dementia and accounted for differences between CN and both prevalent and newly discovered dementia. Ambulatory costs accounted for differences between CN and MCI. Age-, sex-, education-adjusted differences reached significance for CN versus newly discovered and prevalent dementia and for MCI versus prevalent dementia. After considering all comorbid diagnoses, between-category differences were reduced (e.g., prevalent dementia minus MCI (from $4842 to $3575); newly discovered dementia minus CN (from $3578 to $711)). Following the exclusion of neuropsychiatric diagnoses from comorbidity adjustment, between-category differences tended to revert to greater differences.
conclusionsCost estimates did not differ significantly between CN and MCI. Substantial differences between MCI and prevalent dementia reflected high inpatient costs for dementia and appear partly related to co-occurring mental disorders. Such comparisons can help inform models aimed at identifying where, when, and for which individuals proposed interventions might be cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.